Desidustat has reached > 60,000 patients in India NDA filed in China by CMS Pharma

Desidustat is a hypoxia inducible factor-prolyl hydroxylase inhibitor and stimulates EPO production in a similar manner that happens in response to hypoxia. PHD inhibitor which offers promise in treating a range of health disorders such as anemia, ulcerative colitis, myocardial ischemia, stroke, and metabolic disorders those lead to hypoxia. Thus, Desidustat pharmacologically stimulates erythropoiesis via the HIF pathway and in a manner consistent with the body’s normal homeostatic response to hypoxia.

Desidustat has been approved in India recently for treatment of proven to be efficacious and safe in increasing hemoglobin level in anemia in patients with chronic kidney disease on dialysis and not on dialysis. The New Drug Application (NDA) of Desidustat Tablets has been accepted by the National Medical Products Administration of China (NMPA). We has also competed the enrollment of a Phase IIa POC trial to evaluate efficacy and safety of Desidustat oral tablet for treatment of sickle cell disease [CTRI Registration: CTRI/2024/06/068363]. We has recently got approval to conduct a Phase III trial in Chemotherapy Induced Anemia patients.